- Home
- SBFG vs GNLX Comparison
SBFG vs GNLX Comparison
Compare SBFG & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SBFG | GNLX |
|---|---|---|
| Founded | 1983 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 136.9M | 132.7M |
| IPO Year | 2014 | 2022 |
Fundamental Metrics
Financial Performance| Metric | SBFG | GNLX |
|---|---|---|
| Price | $23.01 | $2.97 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $17.25 |
| AVG Volume (30 Days) | 13.6K | ★ 155.4K |
| Earning Date | 04-23-2026 | 05-12-2026 |
| Dividend Yield | ★ 2.98% | N/A |
| EPS Growth | ★ 27.33 | 9.47 |
| EPS | ★ 0.69 | N/A |
| Revenue | N/A | ★ $8,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $32.38 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.28 | $2.29 |
| 52 Week High | $23.93 | $8.54 |
Technical Indicators
Market Signals| Indicator | SBFG | GNLX |
|---|---|---|
| Relative Strength Index (RSI) | 56.35 | 49.96 |
| Support Level | $20.94 | $2.33 |
| Resistance Level | $23.93 | $2.97 |
| Average True Range (ATR) | 0.76 | 0.17 |
| MACD | 0.05 | -0.02 |
| Stochastic Oscillator | 67.47 | 53.12 |
Price Performance
Historical ComparisonAbout SBFG SB Financial Group Inc.
SB Financial Group Inc that provides a range of community banking services, including commercial and consumer lending, personal and business banking, treasury management and merchant services, personal wealth management and brokerage services, and other financial services to individuals, businesses, and municipalities. It operates in a single segment, which is Banking.
About GNLX Genelux Corporation
Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.